Cytokinetics CYTK Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$784.96M-33.2% | -$589.53M-12.0% | -$526.24M-35.3% | -$388.96M-80.6% | ||
| $10.13M+6.2% | $9.53M-19.9% | $11.89M+105% | $5.81M+155% | ||
| $112.29M+14.8% | $97.84M+35.8% | $72.07M+50.6% | $47.85M+78.3% | ||
| $1.11M-92.8% | $15.37M— | —— | -$56.99M-220% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | $4.52M+329% | ||
| $33.6M+137% | $14.18M-17.1% | $17.1M+52.8% | $11.2M-25.7% | ||
| $2.93M+20.3% | $2.44M+253% | -$1.6M— | —— | ||
| -$6.25M— | —— | -$9.59M-136% | -$4.06M— | ||
| —— | —— | $0+100% | -$87M— | ||
| -$510.01M-28.8% | -$395.89M+4.5% | -$414.33M-38.3% | -$299.52M-110% | ||
| $24.81M+535% | $3.91M+176% | $1.42M-87.5% | $11.34M-76.8% | ||
| $1.06B-17.8% | $1.29B+104% | $635.21M-25.7% | $855.39M+62.9% | ||
| —— | $0— | —— | $0— | ||
| —— | —— | —— | —— | ||
| $729.46M— | $0— | $0-100% | $523.59M— | ||
| $10.81M+24.5% | $8.68M— | $0— | —— | ||
| $35.98M— | —— | $172.16M— | —— | ||
| —— | $939K+9.4% | $858K-9.1% | $944K— | ||
| $2.47M— | —— | —— | —— | ||
| $524.46M-43.6% | $930.61M+320% | $221.32M-57.1% | $516.17M+61.3% | ||
| —— | $209K+1,145% | -$20K— | —— | ||
| —— | —— | —— | —— | ||
| $22.91M-11.8% | $25.97M+152% | $10.3M-32.1% | $15.17M+65.3% | ||
| $4.2M+223% | $1.3M— | $0— | $0— | ||
| $0+100% | -$45K— | $0— | $0— | ||
| —— | —— | —— | $4.52M+329% | ||
| —— | —— | $0+100% | -$87M— | ||
| -$10.84M-49.6% | -$7.24M-415% | -$1.41M-181% | $1.73M-96.0% | ||
| -$6.25M— | —— | -$9.59M-136% | -$4.06M— | ||
| $2.93M+20.3% | $2.44M+253% | -$1.6M— | —— | ||
| -$15.98M+50.9% | -$32.52M-107% | -$15.74M-234% | -$4.71M-196% | ||
| —— | -$19.6M— | $0— | $0— | ||
| $58.37M+19.3% | $48.92M+66.0% | $29.47M-7.5% | $31.86M+145% | ||
| $5.65M+30.9% | $4.31M+15.0% | $3.75M+45.1% | $2.59M-64.9% | ||
| $22.9M+98.1% | $11.56M— | —— | $5.7M-20.0% | ||
| $25K— | —— | -$35K+67.3% | -$107K— | ||
| $1.1B+48.3% | $744.23M-14.5% | $870.91M+44.0% | $604.59M+43.0% | ||
| —— | $939K+9.4% | $858K-9.1% | $944K— | ||
| $175M-12.5% | $200M+300% | $50M— | —— | ||
| —— | $50M— | —— | $0— | ||
| $35.98M-32.1% | $53.02M+187% | $18.46M+5.2% | $17.54M— | ||
| —— | —— | $0— | —— | ||
| —— | $509K— | $0-100% | $10.9M— | ||
| -$534.82M-33.8% | -$399.8M+3.8% | -$415.75M-33.7% | -$310.85M-62.4% | ||
| -$534.82M-33.8% | -$399.8M+3.8% | -$415.75M-33.7% | -$310.85M-62.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytokinetics generate?
- Cytokinetics (CYTK) generated -$523.8M in operating cash flow over the trailing twelve months.
- What is Cytokinetics's free cash flow?
- After $25.1M of capital expenditures, Cytokinetics's free cash flow was -$548.9M over the trailing twelve months, down 34.7% year over year.
- Where does Cytokinetics's cash flow data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
